Multiple Sclerosis Trial, Recruiting NCT06860932 Sponsor: Hunter College of City University of New York Condition: Multiple Sclerosis
Back to Multiple Sclerosis

Multiple Sclerosis Trial, Recruiting

NCT06860932
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been diagnosed with MS (Multiple Sclerosis), NMOSD, or anti-MOG disease for at least 2 years.
  • People aged between 18 and 65 years old.
  • People who speak English, as all study materials are only available in English.

Who may not be able to join:

  • People who have a visual impairment (note: people with hearing impairments are not excluded, as the study video includes closed captions).
  • People whose current mental health state is not considered suitable for palliative care discussions, based on the results of a standard questionnaire called the PHQ9. Those who score 11 or higher on this questionnaire — which may suggest major depression — would be referred for immediate support and would not be included in the study.
  • People whose thinking or processing speed makes it difficult to take part in palliative care discussions, based on results from a cognitive test called the Processing Speed Test. A score below a certain threshold on this test may mean the trial site determines the person is not able to participate.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 26 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: 6462262616

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Hunter College of City University of New York
Registry
ClinicalTrials.gov
Start date
1 February 2025
Est. completion
1 June 2026

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Palliative care preferences (i.e., care considerations, discontinuation of care, versus continued full care) for neurological care (Aim 1).

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov